Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or
“Novo”), pioneering a holistic approach to patient-first health and
wellness through a multidisciplinary healthcare ecosystem of
multiple patient and consumer touchpoints for services and product
innovation, today announced that Joseph M. Chalil, MD, MBA, FACHE,
Chief Medical Officer of Novo, Global Healthcare Executive and
Best-Selling Author, was recently selected as Top Physician of the
Year for 2022 by the International Association of Top Professionals
(IAOTP) for his outstanding leadership, dedication, and innovative
medical contributions.
While inclusion with the International Association of Top
Professionals is an honor in itself, only a few members in each
discipline are chosen for this distinction. These special honorees
are distinguished based on their professional accomplishments,
academic achievements, leadership abilities, other affiliations,
and contributions to their communities. All honorees are invited to
attend the IAOTP’s annual awards gala at the end of this year for a
night to honor their achievements.
Stephanie Cirami, IAOTP President, stated, “We are honored to
have Dr. Chalil as part of our IAOTP family. He is brilliant at
what he does, has a unique understanding of health policies, and a
diverse medical background. We know he will be an amazing asset to
our network of professionals.”
Dr. Chalil has over 20 years of professional experience in
health policy, medical affairs, and clinical development with an
emphasis on both healthcare delivery and biotechnology. Previously,
Dr. Chalil has held roles of increasing responsibility at DBV
Technologies, Boehringer Ingelheim, Abbott Laboratories, and
Hoffmann-La Roche. Dr. Chalil was the honored recipient of the AAPI
Presidential Award (2015) and the Boehringer President’s Club Award
for 2011, 2014, and 2015. Dr. Chalil was also recognized and
honored with the 2013 Outstanding 50 Asian Americans in Business
Award.
Dr. Chalil is an author of several scientific and research
papers in international publications. He is also the Chairman of
the Complex Health Systems Advisory Board, H. Wayne Huizenga
College of Business and Entrepreneurship at Nova Southeastern
University in Florida, and a member of Dr. Kiran C. Patel College
of Allopathic Medicine Executive Leadership Council. A veteran of
the U.S. Navy Medical Corps, he is board certified in healthcare
management. He has been awarded a Fellowship by the American
College of Healthcare Executives, an international professional
society of more than 40,000 healthcare executives who lead
hospitals, healthcare systems, and other healthcare organizations.
Additionally, Dr. Chalil is the former Chairman of the
Indo-American Press Club. He is an expert in U.S. healthcare policy
and a strong advocate for patient-centered care. A strong proponent
of providing healthcare access to everyone, Dr. Chalil’s new book,
Beyond the COVID-19 Pandemic: Envisioning a Better World by
Transforming the Future of Healthcare, is on Amazon’s Best Sellers
List.
For more information on Dr. Chalil, please visit:
https://www.linkedin.com/in/drchalil/
About IAOTP
The International Association of Top Professionals (IAOTP) is an
international boutique networking organization that handpicks the
world’s finest, most prestigious top professionals from different
industries. These top professionals are given an opportunity to
collaborate, share their ideas, be keynote speakers, and to help
influence others in their fields. This organization is not a
membership that anyone can join. You must be asked by the President
or be nominated by a distinguished honorary member after a brief
interview.
IAOTP’s experts have given thousands of top prestigious
professionals around the world the recognition and credibility that
they deserve and have helped in building their branding empires.
IAOTP prides itself to be a one-of-a-kind boutique networking
organization that hand picks only the best of the best and creates
a networking platform that connects and brings these top
professionals together.
For more information on IAOTP, please visit
www.iaotp.com. For more information on the IAOTP Awards
Gala, please visit www.iaotp.com/award-gala.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of multiple patient and consumer touchpoints
for services and product innovation. Novo offers an essential and
differentiated solution to deliver, or intend to deliver, these
services and products through the integration of medical
technology, diagnostic and therapeutic solutions, and
rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity, is an
essential solution to the rapidly evolving fundamental
transformation of how non-catastrophic healthcare is delivered both
now and in the future. Specific to non-critical care, ongoing
advancements in both medical technology and inter-connectivity are
allowing for a shift of the patient/practitioner relationship to
the patient’s home and away from on-site visits to primary medical
centers with mass-services. This acceleration of “ease-of-access”
in the patient/practitioner interaction for non-critical care
diagnosis and subsequent treatment minimizes the degradation of
non-critical health conditions to critical conditions as well as
allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is
centered on three primary pillars to best support the
transformation of non-catastrophic healthcare delivery to patients
and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary
primary care services through (i) an affiliate network of clinic
facilities, (ii) small and micro footprint sized clinic facilities
primarily located within the footprint of box-store commercial
enterprises, (iii) clinic facilities operated through a franchise
relationship with the Company, and (iv) corporate operated clinic
facilities.
- Second Pillar: Technology. Develop, deploy, and integrate
sophisticated interconnected technology, interfacing the patient to
the healthcare practitioner thus expanding the reach and
availability of the Company’s services, beyond the traditional
clinic location, to geographic areas not readily providing
advanced, peripheral based healthcare services, including the
patient’s home.
- Third Pillar: Products. Develop and distribute effective,
personalized health and wellness product solutions allowing for the
customization of patient preventative care remedies and ultimately
a healthier population. The Company’s science-first approach to
product innovation further emphasizes our mandate to create and
provide over-the-counter preventative and maintenance care
solutions.
Innovation through science combined with the integration of
sophisticated, secure technology assures Novo Integrated Sciences
of continued cutting-edge advancement in patient first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on Novo
Healthnet Limited, Novo’s wholly owned subsidiary, please visit
www.novohealthnet.com.
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown,
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220426005389/en/
Chris David, COO-President Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (888) 512-1195
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024